Aardvark Therapeutics (AARD), trading on Nasdaq as an Emerging Growth Company, filed an 8-K on November 4, 2025, disclosing pipeline data presented at ObesityWeek 2025 and scheduling an investor webinar for November 5, 2025, to review findings. The updates focus on novel obesity candidates designed to address limitations of existing GLP-1 therapies.
ARD-101 and ARD-201 Strategy: ARD-101, a gut-restricted TAS2R agonist, showed positive preclinical success attenuating weight gain in mice. Phase 2 results (N=14) indicated the drug was well-tolerated with no SAEs, significantly reducing self-
...